Primer on Tumor Immunology and Cancer Immunotherapy™ • Nov. 7, 2019

Thursday, Nov. 7, 2019
8 a.m. 5 p.m.

Program Purpose

The understanding of cancer immunobiology has increased dramatically in recent years, leading to the successful development of novel immune-based treatment options to improve cancer patient outcomes. The SITC Primer on Tumor Immunology and Cancer Immunotherapy™ is designed to provide a foundation for understanding core immunology principles as they relate to basic and clinical research in immunotherapy of cancer.

Intended Audience

The intended audience for this annual, one-day educational program includes students, postdoctoral fellows and technicians from academia and industry, as well as physicians and scientists at more senior levels who wish to solidify their understanding of tumor immunology and immunotherapy, and pharmacists and registered nurses.

Primer Organizers

  • Michael Curran, PhD – The University of Texas MD Anderson Cancer Center
  • Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine
Educational Objectives

Upon completion of this meeting, participants will be able to:

  • Describe the key principles of tumor immunology and immunotherapy
  • Summarize the basic principles of passive immunotherapy, in which antibodies or T lymphocytes generated outside of the patient are administered with therapeutic intent
  • Discuss the techniques involved in active immunotherapy, including tumor antigen vaccination as well as immune checkpoint blockade
  • Outline immune monitoring techniques, both in peripheral blood and sera, as well as in patient samples collected in pre-surgical trials
  • Enhance scientific exchange with colleagues and collaborators on research and application of cancer immunotherapies to improve outcomes of patients with cancer

Program Schedule

Thursday, Nov. 7, 2019

8 8:05 a.m.


Session 1: Tumor Immunity I


8:05 9:55 a.m.

8:05 a.m.

Adaptive Immunity to Tumors and Cytokines: Laying the Foundation for Immunotherapy

8:35 a.m.

Macrophages, Dendritic and Myeloid Cells

9:05 a.m.

Harnessing Natural Killer Cells and Innate Lymphoid Cells to Potentiate Antitumor Immunity

Session 2: Tumor Immunity II



10:10 a.m. 12 p.m.

10:10 a.m.

Immunometabolism and the Microbiome

10:40 a.m.

Cancer Vaccines : From Ex Vivo Production to In Vivo Vaccination

11:10 a.m.

Monoclonal Antibodies and Their Derivatives

11:40 a.m.

Tumor Immunity II Panel Discussion

Session 3: Analysis of Resistance and Response


1 2:55 p.m.

1 p.m.


1:05 p.m.

Mechanisms of Extrinsic Resistance : A Miserable Microenvironment

1:35 p.m.

Mechanisms of Resistance: Checkpoint Receptors

2:05 p.m.

Biomarkers of Response to Immunotherapy

2:35 p.m.

Analysis of Resistance and Response Panel Discussion

Session 4: Current IO Immunotherapy


3:10 4:55 p.m.

3:10 p.m.

Adoptive T Cell Therapy

3:40 p.m.

Combination Therapies

4:10 p.m.

Adverse Events

4:40 p.m.

Current IO Immunotherapy Panel Discussion

4:55 p.m.



Schedule At-a-Glance

Wednesday, Nov. 6
World Immunotherapy Council's 3rd Young Investigator Symposium  
Industry Program
Thursday, Nov. 7

Primer on Tumor Immunology and Cancer Immunotherapy™

Social Activity:
Early Career Scientist Networking Reception

Workshop on Intratumoral Immunomodulation

Meet-the-Expert Lunch
Grant Writing Workshop
34th Annual Meeting
Friday, Nov. 8 34th Annual Meeting

Social Activity:
Poster Reception

Saturday, Nov. 9
34th Annual Meeting Social Activity:
Award Ceremony
Poster Reception
The Checkpoints Band Party
Sunday, Nov. 10 34th Annual Meeting Hot Topic Symposium